Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:27:19.388Z.
Calculation as of: 2026-10-06T15:27:19.388Z.
Quote observation: 2026-10-06T15:25:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48f0cd224d3c7dd52ecd2cde696dbbeed4cc913852df97ed5052446ca25b90ee
PE RATIO
N/A
Market Cap
$78.57M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hyperfine, Inc. (HYPR) | $76.32M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $77.48M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $74.00M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.57M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.02M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $71.19M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $71.05M | N/A | 70.55 | 70.55 | 70.55 |
| LENSAR Inc (LNSR)vs › | $82.66M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.91
Forward EPS (Est.)
$-0.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
